Fact Sheet

About Illumina

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service.

We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Download Illumina @ a Glance Fact Sheet
Quick facts
  • Website:
    illumina.com
  • Ticker symbol:
    ILMN
  • Headquarters:
    San Diego, California, USA
  • Number of employees:
    ~9,250 globally
  • 2023 revenue1:
    $4.50B USD
  • Illumina @ a Glance
    Fact Sheet

The Illumina mission

We take our mission seriously and ingrain it in everything we do.

Our mission statement:
To improve human health by unlocking the power of the genome.

Leading-edge products and services

Illumina has developed a comprehensive line of products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. Our broad portfolio of leading-edge sequencing, software, and array-based solutions addresses a range of genomic complexity and throughput, enabling researchers to select the best solution for their scientific challenge.

Instruments

  • NovaSeq Sequencing Systems
  • NextSeq Sequencing Systems
  • NextSeqDX Sequencing System
  • MiSeq Sequencing System
  • MiSeqDx Sequencing System
  • MiniSeq Sequencing System
  • iSeq 100 System
  • iScan Array Scanner

Assays

  • AmpliSeq for Illumina
  • TruSeq, TruSight, and Nextera technologies
  • Infinium genotyping and methylation assays

Software

  • DRAGEN
  • Illumina Connected Analytics
  • Illumina Connected Insights
  • Illumina Connected Annotations
  • Emedgene
  • Clarity LIMS
  • BaseSpace Sequence Hub
  • Correlation Engine
  • Illumina Run Management

Where we operate

  • San Diego, California, USA
  • Foster City, California, USA
  • Hayward, California, USA
  • Baltimore, Maryland, USA
  • Madison, Wisconsin, USA
  • São Paulo, Brazil
  • Cambridge, UK
  • Mechelen, Belgium
  • Évry, France
  • Rennes, France
  • Berlin, Germany
  • Milan, Italy
  • Tel Aviv, Israel
  • Eindhoven, Netherlands
  • Istanbul, Turkey
  • Dubai, UAE
  • Beijing, China
  • Shanghai, China
  • Guangzhou, China
  • Hangzhou, China
  • Taipei City, China
  • Osaka, Japan
  • Tokyo, Japan
  • Singapore
  • Bengaluru, India
  • Melbourne, Australia
  • Sydney, Australia
  • Seoul, South Korea

Illumina management team

  • Jacob Thaysen, PhD
    Chief Executive Officer
  • Steve Barnard, PhD
    Chief Technology Officer
  • Nicole Berry
    Head of Region—Americas
  • Charles Dadswell
    General Counsel
  • Joydeep Goswami, PhD
    Chief Financial Officer, Chief Strategy and Corporate Development Officer
  • Pat Leckman
    Interim Chief People Officer
  • Max Ma
    Interim Head of Region—Greater China
  • Kevin Pegels
    Chief of Global Operations
  • Kathryne Reeves
    Chief Marketing Officer
  • Carissa Rollins
    Chief Information Officer
  • Salli Schwartz
    Vice President of Investor Relations
  • Bas Verhoef
    Head of Region–Europe
    Interim Chief Commercial Officer
  • Gretchen Weightman
    Head of Region—Asia Pacific, Middle East, & Africa
  1. 2023 Annual Revenue provided in February 2024